Facebook
Twitter
LinkedIn
Forward
Best Practices in Improving Diagnosis and Treatment of Neurotrophic Keratitis (Virtual CME/CE Symposium)
To register for the virtual symposium, please click Register/Take Course.
Tuesday, May 7, 2024
6:30 PM – 8:00 PM PT CME/CE Symposium
This educational symposium is not affiliated with the official program of ARVO 2024
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate corneal sensitivity testing into practice to identify neurotrophic keratitis
- Select appropriate treatment for patients with neurotrophic keratitis using clinical evidence
Faculty
 | Francis S. Mah, MD (Chair) |
 | Douglas K. Devries, OD |
 | Lisa M. Nijm, MD, JD |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Douglas K. Devries, OD, is a consultant for AbbVie Inc, Alcon, Avellino, Azura Ophthalmics, Bausch Health, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharma Inc, and Visus Therapeutics; and is on the speakers bureau for Alcon, Bausch Health, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.
Lisa M. Nijm, MD, JD, is a consultant for AbbVie Inc, Alcon, Amgen Inc, Astellas Pharma Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Nordic Pharma, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, Trukera, and Visus Therapeutics; is an advisory board member of AbbVie Inc, Alcon, Amgen Inc, Astellas Pharma Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, and Trukera; is on the speakers bureau for AbbVie Inc, Amgen Inc, Bausch & Lomb Incorporated, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Ocular Therapeutix, Inc; and has stock options that have not been exercised in Trukera.
Francis S. Mah, MD, is a consultant for Dompé US, Inc*, Kala Pharmaceuticals, and Kiora Pharmaceuticals, Inc*; is an advisory board member of San Diego Eye Bank; and is a contracted researcher for Kala Pharmaceuticals.
* The financial relationship existed during the last 24 months but has now ended
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 91291-TD (Synchronous Virtual)
COPE Course Category: Treatment & Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 128386, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Dompé US, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 322.1
Available Credit
- 1.50 AMA PRA Category 1 Credit™
- 1.50 COPE
- 1.50 Participation
Please login if you already have an account on the MedEdicus Learning Portal OR register to create an account and sign up for this symposium.
If you do not receive an email confirmation, please check your spam folder or email info@mededicus.com.